Growth Metrics

Galectin Therapeutics (GALT) Capital Expenditures (2012)

Galectin Therapeutics' quarterly Capital Expenditures came in at $3000.0 in Q4 2012.

Galectin Therapeutics has reported Capital Expenditures for 1 years, with the latest figure at $3000.0 in Q4 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 133.40 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 230.60 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 21.83 Mn
10 Galectin Therapeutics 165.77 Mn 151.67 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2012 3,000.00
Dec 31, 2012 3,000.00